Florida is one of a handful of states that have applied to import wholesale prescription drugs from Canada. (David Donnelly/CBC)
The Food and Drug Administration (FDA) has approved Florida's groundbreaking plan to import prescription drugs from Canada, to solve the long-standing issue of high U.S. drug prices.
Governor Ron DeSantis signed the plan into law in 2019, and its clearance required federal review and FDA approval. President Joe Biden supports such programs as a means to reduce drug prices, emphasizing this approach in a 2021 executive order.
While the White House sees this as a positive step, Canadian health providers express skepticism due to potential supply challenges and historic drug shortages in Canada.
This policy marks a significant departure in the U.S., challenging pharmaceutical industry lobbying that raised concerns about counterfeit or adulterated drugs. Both political parties, including former President Donald Trump, have shifted towards supporting drug imports.
AARP Florida welcomes the federal decision, acknowledging it as one step in the broader effort to lower prescription drug costs. The FDA authorizes Florida's program for two years, requiring thorough testing, relabeling, and compliance with U.S. standards before drug imports commence. Legal challenges from the pharmaceutical industry are expected, with concerns raised about the decision's impact on public health.
Many individuals already purchase medicines from Canada or Mexico, despite legal restrictions. The initiative to allow state imports began under Trump's administration, emphasizing the need to address industry pricing practices. The state of Florida anticipates significant savings, and Governor DeSantis, who has sued the Biden administration over alleged delays in approval, views it as a victory. However, the pharmaceutical industry's trade organization condemns the FDA's decision, citing it as a "serious danger to public health." The broader context includes ongoing efforts to allow the federal government to negotiate drug prices, with the first negotiations expected later this year.
